Journal
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume 43, Issue 2, Pages 296-298Publisher
WILEY
DOI: 10.1111/jcpt.12641
Keywords
conjunctivitis; erlotinib; ocular changes; toxicity
Categories
Ask authors/readers for more resources
What is known and objectiveErlotinib is one of the epidermal growth factor receptor (EGFR) inhibitors and is widely used as a targeted therapy for advanced non-small-cell lung cancer (NSCLC). There are a few reports regarding ocular adverse effects of erlotinib. Herein, we report a case of rapid onset of ocular toxicity associated with overdosing of erlotinib. Case descriptionA 72-year-old male with metastatic NSCLC developed conjunctivitis after accidentally taking erlotinib at a dosage of 300mg/day for 4days. Before that, the patient had been taking erlotinib at the prescribed dose of 150mg/day for 17days. Erlotinib was discontinued for 7days, and the conjunctivitis was successfully treated symptomatically. The adverse effect did not recur when he resumed taking erlotinib 150mg/day, suggesting the ocular change was related to the overdosing of erlotinib. What is new and conclusionAwareness and close monitoring of this adverse effect are helpful for doctors and pharmacists to identify inadvertent drug overdose. Patients should be provided comprehensive education before receiving targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available